Publication: HIV-1 neutralization by monoclonal antibody against conserved region 2 and patterns of epitope exposure on the surface of native viruses
1
Issued Date
2009
Resource Type
Language
eng
Bibliographic Citation
Journal of Immune Based Therapies and Vaccines. Vol.7, No.5 (2009), 1-8
Suggested Citation
Apichai Sreepian, Jongruk Permmongkol, Wannee Kantakamalakul, Sontana Siritantikorn, Nattaya Tanlieng, Ruengpung Sutthent HIV-1 neutralization by monoclonal antibody against conserved region 2 and patterns of epitope exposure on the surface of native viruses. Journal of Immune Based Therapies and Vaccines. Vol.7, No.5 (2009), 1-8. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/2109
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
HIV-1 neutralization by monoclonal antibody against conserved region 2 and patterns of epitope exposure on the surface of native viruses
Abstract
Background: Conserved neutralizing epitopes are considered to be a key role for eliciting broadly
neutralizing antibody (NAb). Previously, two conserved neutralizing epitopes of HIV-1 CRF01_AE
envelope were identified at amino acid 93-112 of the C1 (C1E) and at 218-239 of the C2 (C2E)
regions. To access the potency of antibody directed against conserved epitopes, a monoclonal
antibody (MAb) specific to the C2E region was developed and characterized.
Methods: The immunogenicity of two epitopes was examined by immunizing BALB/c mice with
the matching synthetic peptides. One MAb, C2EB5, directed against peptide C2E, was generated
by conventional methods, while C1E1 and C1E2 peptides induced slight antibody response in mice.
The neutralizing activity of MAb C2EB5 was examined using a peripheral blood mononuclear cell
(PBMC) based method and various HIV-1 subtypes including A, B, C, D, and CRF01_AE; C2EB5
was compared with other known neutralizing MAbs (4E10, 447-52D) and with sCD4. The
exposure of the C2 epitope on native virus was investigated using virus capture by these MAbs.
Results: The MAb C2EB5 demonstrated cross-neutralization against various HIV-1 subtypes. The
overall potency of MAb C2EB5 against 5 subtypes was ranked in the following order: subtype C>
CRF01_AE> subtype D> subtype A> subtype B. The epitope exposure for MAb C2EB5 was also
correlated with the neutralization properties of each subtype.
Conclusion: This study demonstrates the cross-clade neutralizing activity of a MAb directed
against an epitope located in the C2 region of the HIV-1 env and highlights differences in the
exposure of antigenic epitopes on the surface of various HIV-1 subtypes. The epitope for this newly
identified neutralizing MAb made against a subtype CRF01_AE peptide is particularly exposed in
subtype C viral isolates.
Published: 12 October 2009
Journal of Immune Based Therapies and Vaccines 2009, 7:5 doi:10.1186/1476-8518-7-5
Received: 25 September 2008
Accepted: 12 October 2009
This article is available from: http://www.jibtherapies.com/content/7/1/5
© 2009 Sreepian et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.